Safety and Efficacy of MBI 226 for the Prevention of Cent... | NCT00027248

Studies
Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections

NCT00027248

Sponsor

BioWest Therapeutics Inc

Status

Completed

Last Update Posted

Sep 14, 2005Estimated

Enrollment

1,400

Phase

Phase 3

Conditions

Sepsis
Bacteremia
Fungemia

Interventions

MBI 226

Countries

United States

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Sep 2005

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Not provided

Start Date

Sep 2000

Primary Completion Date

Not provided

Completion Date

Jul 2003

First Submitted Date

Nov 29, 2001

First Submission Date that Met QC Criteria

Nov 29, 2001

First Posted Date

Nov 30, 2001Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Sep 12, 2005

Last Update Posted Date

Sep 14, 2005Estimated

Description Module

Brief Summary

Central venous catheters (CVCs) are used in patient care for such purposes as the administration of medication, fluids, blood products and for functions such as hemodialysis and plasmapheresis. However, the use of CVCs can cause complications such as life-threatening bloodstream infections (BSI).

BSIs are caused by organisms from the skin's surface tracking down the catheter's outer surface. The organisms grow on the catheter surface (catheter colonization) which is followed by seeding into the bloodstream. BSIs can be difficult to treat and the mortality rate is as high as 35% in Intensive Care patients with a catheter-related BSI. It is estimated that up to 70,000 patients in the US die each year from catheter-related BSI.

MBI 226 is a new drug that, when applied to the skin surrounding the catheter insertion site, may prevent organisms on the skin from migrating down the catheter and entering the bloodstream and therefore decrease the incidence of catheter-related BSI in patients with CVCs.

Detailed Description

Not provided

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 3

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

1,400

Name	Type	Description	Arm Group Labels	Other Names
MBI 226	Drug

Measure	Description	Time Frame
Reduction of catheter-related bloodstream infection

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Patients undergoing non-cuffed arterial and/or central venous catheterization.
Patients able to give signed informed consent.
Concurrent antibiotic therapy is permitted.

Exclusion Criteria:

Treatment with an experimental topical, antibacterial, or antifungal drug within the previous 30 days.
Patients who are scheduled to receive catheters impregnated/bonded with an antimicrobial substance.
Patients requiring arterial or central venous catheterization for less than 48 hours or longer than 28 days.
Second or third degree burn patients.
Patients with a suspected or known bloodstream infection or local catheter insertion site infection.
Patients with a known allergy to adhesive tape or adhesive bandages.
Patients with a medical condition that the Investigator believes may interfere with the safety of the patient or the intent or conduct of the study.
Routine non-complicated post-operative CABG patients.
The disinfection procedure for catheter insertion did not include povidone-iodine.

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

16 Years

Maximum Age

Not provided

Standard Ages

ChildAdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Name	Affiliation	Role
Jim Pankovich	BioWest Therapeutics Inc	Study Director

Facility	Status	City	State	ZIP	Country	Contacts
Omnicare Clinical Research Inc.		Lake Bluff	Illinois	60044	United States

Condition Browse Module

MeSH Terms

ID	Term
D018805	Sepsis
D016470	Bacteremia
D016469	Fungemia

Ancestor Terms

ID	Term
D007239	Infections
D018746	Systemic Inflammatory Response Syndrome
D007249	Inflammation
D010335	Pathologic Processes

Browse Leaves

Not provided

Browse Branches

Not provided

Measure	Description	Time Frame
Reduction of catheter colonization
Reduction of local catheter site infection